neoplasm metastasis

Summary

Summary: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Top Publications

  1. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
  2. ncbi Epithelial-mesenchymal transitions in development and disease
    Jean Paul Thiery
    IMCB, A STAR, Proteos, Singapore 138673, Republic of Singapore
    Cell 139:871-90. 2009
  3. pmc Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
  4. pmc Inflammation and cancer
    Lisa M Coussens
    Cancer Research Institute, Department of Pathology, University of California, San Francisco, California 94143, USA
    Nature 420:860-7. 2002
  5. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
  6. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
  7. ncbi Cancer metastasis: building a framework
    Gaorav P Gupta
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 127:679-95. 2006
  8. pmc Tumor metastasis: molecular insights and evolving paradigms
    Scott Valastyan
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 147:275-92. 2011
  9. ncbi Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:682-8. 2007
  10. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006

Detail Information

Publications298 found, 100 shown here

  1. ncbi Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
    Antoine E Karnoub
    Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:557-63. 2007
    ..Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells...
  2. ncbi Epithelial-mesenchymal transitions in development and disease
    Jean Paul Thiery
    IMCB, A STAR, Proteos, Singapore 138673, Republic of Singapore
    Cell 139:871-90. 2009
    ....
  3. pmc Prospective identification of tumorigenic breast cancer cells
    Muhammad Al-Hajj
    Department of Internal Medicine, Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Proc Natl Acad Sci U S A 100:3983-8. 2003
    ..Furthermore, because these cells drive tumor development, strategies designed to target this population may lead to more effective therapies...
  4. pmc Inflammation and cancer
    Lisa M Coussens
    Cancer Research Institute, Department of Pathology, University of California, San Francisco, California 94143, USA
    Nature 420:860-7. 2002
    ..These insights are fostering new anti-inflammatory therapeutic approaches to cancer development...
  5. ncbi Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Herbert Hurwitz
    Duke University, Durham, NC, USA
    N Engl J Med 350:2335-42. 2004
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy...
  6. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  7. ncbi Cancer metastasis: building a framework
    Gaorav P Gupta
    Cancer Biology and Genetics Program, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 127:679-95. 2006
    ..Recent conceptual and technological advances promote our understanding of the origins and nature of cancer metastasis...
  8. pmc Tumor metastasis: molecular insights and evolving paradigms
    Scott Valastyan
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 147:275-92. 2011
    ..Recent advances provide provocative insights into these cell-biological and molecular changes, which have implications regarding the steps of the invasion-metastasis cascade that appear amenable to therapeutic targeting...
  9. ncbi Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nature 449:682-8. 2007
    ....
  10. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  11. ncbi Involvement of chemokine receptors in breast cancer metastasis
    A Muller
    Department of Immunology, DNAX Research Institute, Palo Alto, California 94304, USA
    Nature 410:50-6. 2001
    ..Our findings indicate that chemokines and their receptors have a critical role in determining the metastatic destination of tumour cells...
  12. ncbi Identification of selective inhibitors of cancer stem cells by high-throughput screening
    Piyush B Gupta
    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Cell 138:645-59. 2009
    ..This study demonstrates the ability to identify agents with specific toxicity for epithelial CSCs...
  13. ncbi A perspective on cancer cell metastasis
    Christine L Chaffer
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
    Science 331:1559-64. 2011
    ....
  14. ncbi Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis
    Jing Yang
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell 117:927-39. 2004
    ..These results establish a mechanistic link between Twist, EMT, and tumor metastasis...
  15. pmc Microenvironmental regulation of metastasis
    Johanna A Joyce
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, USA
    Nat Rev Cancer 9:239-52. 2009
    ..This Review describes experimental data demonstrating the role of the microenvironment in metastasis, identifies areas for future research and suggests possible new therapeutic avenues...
  16. ncbi Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis
    Jing Yang
    Department of Pharmacology and Pediatrics, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0636, USA
    Dev Cell 14:818-29. 2008
    ..Studies in both fields are critical for our molecular understanding of cell migration and morphogenesis...
  17. ncbi A gene-expression signature as a predictor of survival in breast cancer
    Marc J van de Vijver
    Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    N Engl J Med 347:1999-2009. 2002
    ..A more accurate means of prognostication in breast cancer will improve the selection of patients for adjuvant systemic therapy...
  18. ncbi Fibroblasts in cancer
    Raghu Kalluri
    Center for Matrix Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Rev Cancer 6:392-401. 2006
    ..Fibroblasts are therefore a key determinant in the malignant progression of cancer and represent an important target for cancer therapies...
  19. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
    ....
  20. ncbi Macrophage diversity enhances tumor progression and metastasis
    Bin Zhi Qian
    Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cell 141:39-51. 2010
    ..Specialized subpopulations of macrophages may represent important new therapeutic targets...
  21. ncbi The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited
    Isaiah J Fidler
    Department of Cancer Biology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Nat Rev Cancer 3:453-8. 2003
    ..How has this field developed over the past century, and what major breakthroughs are most likely to lead to effective therapeutic approaches?..
  22. ncbi Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet 372:449-56. 2008
    ..We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy...
  23. ncbi Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
    Eric Van Cutsem
    University Hospital Gasthuisberg, Digestive Oncology Unit, Herestraat 49, 3000 Leuven, Belgium
    N Engl J Med 360:1408-17. 2009
    ....
  24. ncbi Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways
    Tamer T Onder
    Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
    Cancer Res 68:3645-54. 2008
    ..These findings indicate that E-cadherin loss in tumors contributes to metastatic dissemination by inducing wide-ranging transcriptional and functional changes...
  25. pmc Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:3584-90. 2009
    ..Final survival analyses and updated results are reported...
  26. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  27. pmc Endogenous human microRNAs that suppress breast cancer metastasis
    Sohail F Tavazoie
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 451:147-52. 2008
    ..miR-335 and miR-126 are thus identified as metastasis suppressor microRNAs in human breast cancer...
  28. ncbi Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
    Patrick C Hermann
    Department of Surgery, Ludwig Maximilians University, 81377 Munich, Germany
    Cell Stem Cell 1:313-23. 2007
    ..Strategies aimed at modulating the SDF-1/CXCR4 axis may have important clinical applications to inhibit metastasis of cancer stem cells...
  29. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  30. ncbi Matrix metalloproteinases and tumor metastasis
    Elena I Deryugina
    Department of Cell Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
    Cancer Metastasis Rev 25:9-34. 2006
    ..This dual function of individual MMPs in metastasis has become a major focus of this review...
  31. ncbi Metastasis: from dissemination to organ-specific colonization
    Don X Nguyen
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Rev Cancer 9:274-84. 2009
    ....
  32. ncbi MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer
    I A Asangani
    Department of Experimental Surgery and Molecular Oncology of Solid Tumors, Medical Faculty Mannheim, University of Heidelberg, Germany
    Oncogene 27:2128-36. 2008
    ..This is the first study to show that Pdcd4 is negatively regulated by miR-21. Furthermore, it is the first report to demonstrate that miR-21 induces invasion/intravasation/metastasis...
  33. ncbi let-7 regulates self renewal and tumorigenicity of breast cancer cells
    Fengyan Yu
    Department of Breast Surgery, No 2 Affiliated Hospital, Sun Yat Sen University, Guangzhou 510120, People s Republic of China
    Cell 131:1109-23. 2007
    ..Therefore let-7 regulates multiple BT-IC stem cell-like properties by silencing more than one target...
  34. ncbi Molecular requirements for epithelial-mesenchymal transition during tumor progression
    Margit A Huber
    Department of Dermatology, Vienna Medical University, Wahringer Gurtel 18 20, 1090 Vienna, Austria
    Curr Opin Cell Biol 17:548-58. 2005
    ..Increasing evidence suggests that EMT plays a specific role in the migration of cells from a primary tumor into the circulation and may provide a rationale for developing more effective cancer therapies...
  35. ncbi Dissemination and growth of cancer cells in metastatic sites
    Ann F Chambers
    London Regional Cancer Centre, London, Ontario N6A 4L6, Canada
    Nat Rev Cancer 2:563-72. 2002
    ..Inhibition of the growth of metastases in secondary sites offers a promising approach for cancer therapy...
  36. ncbi Tumor metastasis: mechanistic insights and clinical challenges
    Patricia S Steeg
    Women s Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute Building 37, Room 1122, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:895-904. 2006
  37. ncbi Role of angiogenesis in tumor growth and metastasis
    Judah Folkman
    Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA, USA
    Semin Oncol 29:15-8. 2002
    ..Phase 1 clinical trials of endostatin and angiostatin are ongoing, and preliminary results show minimal toxicities...
  38. pmc Genes that mediate breast cancer metastasis to the brain
    Paula D Bos
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 459:1005-9. 2009
    ..This co-option of a brain sialyltransferase highlights the role of cell-surface glycosylation in organ-specific metastatic interactions...
  39. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
    ....
  40. pmc Generation of breast cancer stem cells through epithelial-mesenchymal transition
    Anne Pierre Morel
    Centre Leon Berard, Lyon, France
    PLoS ONE 3:e2888. 2008
    ..The acquisition of these stem and tumorigenic characters is driven by EMT induction...
  41. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  42. pmc A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells
    Ulrike Burk
    Department of Visceral Surgery, University of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    EMBO Rep 9:582-9. 2008
    ..Alternatively, depending on the environmental trigger, this loop might switch and induce epithelial differentiation, and thus explain the strong intratumorous heterogeneity observed in many human cancers...
  43. pmc The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2
    Manav Korpal
    Department of Molecular Biology, Princeton University, Princeton, NJ 08544, USA
    J Biol Chem 283:14910-4. 2008
    ..These results suggested that loss of expression of the miR-200 family members may play a critical role in the repression of E-cadherin by ZEB1 and ZEB2 during EMT, thereby enhancing migration and invasion during cancer progression...
  44. ncbi Epithelial-mesenchymal transitions: twist in development and metastasis
    Yibin Kang
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cell 118:277-9. 2004
    ..A recent report in Cell (Yang et al., 2004) adds Twist to this list and links EMT to the ability of breast cancer cells to enter the circulation and seed metastases...
  45. pmc miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nat Cell Biol 12:247-56. 2010
    ..These findings uncover a regulatory and signalling pathway involving a metastasis-promoting miRNA that is predicted to directly target expression of the key metastasis-suppressing protein E-cadherin...
  46. ncbi Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Room H 917, New York, NY 10021, USA
    J Clin Oncol 26:2013-9. 2008
    ....
  47. ncbi EMT, the cytoskeleton, and cancer cell invasion
    Mahmut Yilmaz
    Institute of Biochemistry and Genetics, Department of Biomedicine, University of Basel, Basel, Switzerland
    Cancer Metastasis Rev 28:15-33. 2009
    ..In this review, we have summarized recent novel insights into the molecular processes and players underlying EMT on one side and the formation of invasive membrane protrusions on the other side...
  48. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  49. pmc A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis
    Scott Valastyan
    Whitehead Institute for Biomedical Research, Cambridge, MA 02142, USA
    Cell 137:1032-46. 2009
    ..Indeed, RhoA re-expression partially reverses miR-31-imposed metastasis suppression. These findings indicate that miR-31 uses multiple mechanisms to oppose metastasis...
  50. ncbi Met, metastasis, motility and more
    Carmen Birchmeier
    Department of Neuroscience, Max Delbruck Center for Molecular Medicine, Robert Rossle Strasse 10, 13122 Berlin, Germany
    Nat Rev Mol Cell Biol 4:915-25. 2003
  51. ncbi Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer
    Steven J Cohen
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 26:3213-21. 2008
    ..We tested the hypothesis that circulating tumor cells (CTCs) could predict clinical outcome in patients with mCRC...
  52. pmc Isolation of rare circulating tumour cells in cancer patients by microchip technology
    Sunitha Nagrath
    Surgical Services and BioMEMS Resource Center, Massachusetts General Hospital, Harvard Medical School, and Shriners Hospital for Children, Boston, Massachusetts 02114, USA
    Nature 450:1235-9. 2007
    ..It has broad implications in advancing both cancer biology research and clinical cancer management, including the detection, diagnosis and monitoring of cancer...
  53. ncbi Distinct role of macrophages in different tumor microenvironments
    Claire E Lewis
    Academic Unit of Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, United Kingdom
    Cancer Res 66:605-12. 2006
    ..This review will discuss the evidence for differential regulation of TAMs in these microenvironments and provide an overview of current attempts to target or use TAMs for therapeutic purposes...
  54. pmc CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors
    Sergey V Shmelkov
    Howard Hughes Medical Institute, Ansary Center for Stem Cell Therapeutics, and Department of Genetic Medicine, Weill Medical College of Cornell University, New York, New York, USA
    J Clin Invest 118:2111-20. 2008
    ....
  55. ncbi Macrophages: obligate partners for tumor cell migration, invasion, and metastasis
    John Condeelis
    Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    Cell 124:263-6. 2006
    ..Thus, macrophages are at the center of the invasion microenvironment and are an important drug target for cancer therapy...
  56. ncbi Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    Jolien Tol
    Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    N Engl J Med 360:563-72. 2009
    ..We studied the effect of adding the anti-epidermal growth factor receptor (EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer...
  57. ncbi Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
    W Jeffrey Allard
    Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
    Clin Cancer Res 10:6897-904. 2004
    ..5 mL of blood in healthy subjects, patients with nonmalignant diseases, and patients with a variety of metastatic carcinomas...
  58. pmc The patterns and dynamics of genomic instability in metastatic pancreatic cancer
    Peter J Campbell
    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK
    Nature 467:1109-13. 2010
    ..These data attest to the richness of genetic variation in cancer, brought about by the tandem forces of genomic instability and evolutionary selection...
  59. pmc VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
    Rosandra N Kaplan
    Department of Pediatrics and the Children s Blood Foundation Laboratories, Weill Cornell Medical College of Cornell University, New York, New York 10021, USA
    Nature 438:820-7. 2005
    ..These findings demonstrate a requirement for VEGFR1+ haematopoietic progenitors in the regulation of metastasis, and suggest that expression patterns of fibronectin and VEGFR1+VLA-4+ clusters dictate organ-specific tumour spread...
  60. ncbi Rho GTPases in cancer cell biology
    Francisco M Vega
    Randall Division of Cell and Molecular Biophysics, King s College London, New Hunt s House, Guy s Campus, London SE1 1UL, UK
    FEBS Lett 582:2093-101. 2008
    ..Here, we discuss how Rho GTPases could contribute to different steps of cancer progression, including proliferation, survival, invasion and metastasis...
  61. ncbi Tumour-educated macrophages promote tumour progression and metastasis
    Jeffrey W Pollard
    Center for the Study of Reproductive Biology and Women s Health and the Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, New York 10461, USA
    Nat Rev Cancer 4:71-8. 2004
  62. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  63. ncbi A MicroRNA targeting dicer for metastasis control
    Graziano Martello
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padua School of Medicine, viale Colombo 3, 35126 Padua, Italy
    Cell 141:1195-207. 2010
    ..These findings suggest a new pathway by which Dicer inhibition drifts epithelial cancer toward a less-differentiated, mesenchymal fate to foster metastasis...
  64. pmc Repeated observation of breast tumor subtypes in independent gene expression data sets
    Therese Sorlie
    Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 100:8418-23. 2003
    ..Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities...
  65. ncbi Breast cancer metastasis: markers and models
    Britta Weigelt
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Rev Cancer 5:591-602. 2005
    ..These data have important implications for prognosis prediction and our understanding of metastasis...
  66. ncbi Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Cell 8:393-406. 2005
    ....
  67. ncbi Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer
    Carsten Bokemeyer
    University Hospital, Hamburg Eppendorf, Hamburg Eppendorf, Germany
    J Clin Oncol 27:663-71. 2009
    ..The influence of KRAS mutation status was investigated...
  68. ncbi Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways
    Lionel Larue
    Developmental Genetics of Melanocytes, UMR 146, CNRS, Institut Curie, Centre Universitaire, Orsay, France
    Oncogene 24:7443-54. 2005
    ..Interactions between PI3K/AKT and other EMT-inducing pathways are presented, along with a discussion of the therapeutic implications of modulating EMT in order to achieve cancer control...
  69. ncbi Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
    Wendy De Roock
    Center for Human Genetics, University of Leuven, Leuven, Belgium
    JAMA 304:1812-20. 2010
    ..Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab...
  70. ncbi CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment
    Jan A Burger
    Department of Leukemia, Unit 428, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Blood 107:1761-7. 2006
    ..As such, CXCR4 antagonists, although initially developed for treatment of AIDS, actually may become effective agents for the treatment of neoplastic disease...
  71. pmc Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
    Sunhwa Kim
    Department of Pharmacology and Cancer Center, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093 0723, USA
    Nature 457:102-6. 2009
    ..These results explain how advanced cancer cells usurp components of the host innate immune system, including bone-marrow-derived myeloid progenitors, to generate an inflammatory microenvironment hospitable for metastatic growth...
  72. ncbi A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    J Randolph Hecht
    David Geffen School of Medicine at UCLA, Santa Monica, CA 90404, USA
    J Clin Oncol 27:672-80. 2009
    ..This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC...
  73. ncbi Systemic spread is an early step in breast cancer
    Yves Hüsemann
    Department of Pathology, Division of Oncogenomics, University of Regensburg, Regensburg 93053, Germany
    Cancer Cell 13:58-68. 2008
    ..Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis...
  74. ncbi Interactions between cancer stem cells and their niche govern metastatic colonization
    Ilaria Malanchi
    Ecole Polytechnique Federale de Lausanne, Swiss Institute for Experimental Cancer Research and National Center of Competence in Research Molecular Oncology, 1015 Lausanne, Switzerland
    Nature 481:85-9. 2012
    ..We suggest that the education of stromal cells by infiltrating tumour cells is an important step in metastatic colonization and that preventing de novo niche formation may be a novel strategy for the treatment of metastatic disease...
  75. ncbi Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
    C M Balch
    Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Clin Oncol 19:3622-34. 2001
    ..Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,450 melanoma patients from their databases in order to validate this staging proposal...
  76. pmc Genes that mediate breast cancer metastasis to lung
    Andy J Minn
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nature 436:518-24. 2005
    ..Others contribute to aggressive growth selectively in the lung. Many encode extracellular proteins and are of previously unknown relevance to cancer metastasis...
  77. pmc Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature
    Emmanuelle Charafe-Jauffret
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm Institut Paoli Calmettes, Universite de la Mediterranee, Marseille, France
    Cancer Res 69:1302-13. 2009
    ....
  78. pmc Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271
    Alexander D Boiko
    Institute for Stem Cell Biology and Regenerative Medicine, Stanford Cancer Center, Stanford University School of Medicine, Stanford, California 94304 5542, USA
    Nature 466:133-7. 2010
    ....
  79. ncbi A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis
    Maddalena Adorno
    Department of Histology, Microbiology and Medical Biotechnologies, University of Padua School of Medicine, viale Colombo 3, 35100 Padua, Italy
    Cell 137:87-98. 2009
    ..Thus, two common oncogenic lesions, mutant-p53 and Ras, selected in early neoplasms to promote growth and survival, also prefigure a cellular set-up with particular metastasis proclivity by TGFbeta-dependent inhibition of p63 function...
  80. ncbi Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells
    L Patrawala
    Department of Carcinogenesis, The University of Texas MD Anderson Cancer Center, Science Park Research Division, Smithville, 78957, USA
    Oncogene 25:1696-708. 2006
    ..Altogether, our results suggest that the CD44(+) PCa cell population is enriched in tumorigenic and metastatic progenitor cells...
  81. ncbi Cancer stem cells in solid tumours: accumulating evidence and unresolved questions
    Jane E Visvader
    VBCRC Laboratory, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria 3050, Australia
    Nat Rev Cancer 8:755-68. 2008
    ..The clinical relevance of CSCs remains a fundamental issue but preliminary findings indicate that specific targeting may be possible...
  82. pmc Comparative lesion sequencing provides insights into tumor evolution
    Sian Jones
    The Ludwig Center for Cancer Genetics and Therapeutics, Department of Biostatistics, Howard Hughes Medical Institute, and Sidney Kimmel Cancer Center at The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 105:4283-8. 2008
    ..These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis...
  83. ncbi Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  84. pmc Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis
    Li Yang
    Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Cancer Cell 13:23-35. 2008
    ..Together, these data indicate that Gr-1+CD11b+ cells contribute to TGFbeta-mediated metastasis through enhancing tumor cell invasion and metastasis...
  85. pmc Latent bone metastasis in breast cancer tied to Src-dependent survival signals
    Xiang H F Zhang
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Cell 16:67-78. 2009
    ..Breast cancer cells that lodge in the bone marrow succumb in this environment when deprived of Src activity...
  86. ncbi Parallel progression of primary tumours and metastases
    Christoph A Klein
    Division of Oncogenomics, Department of Pathology, University of Regensburg, 93053 Regensburg, Germany
    Nat Rev Cancer 9:302-12. 2009
    ..Consideration of this model urges review of current diagnostic and therapeutic routines...
  87. ncbi Cancer and the chemokine network
    Fran Balkwill
    Cancer Research UK Translational Oncology Laboratory, Barts and The London, Queen Mary s Medical School, Charterhouse Square, London EC1M 6BQ, UK
    Nat Rev Cancer 4:540-50. 2004
  88. pmc Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis
    Esmeralda Casas
    Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, California 92093 0636, USA
    Cancer Res 71:245-54. 2011
    ..Together, our results show that Twist1 needs to induce Snail2 to suppress the epithelial branch of the EMT program and that Twist1 and Snail2 act together to promote EMT and tumor metastasis...
  89. ncbi Direct regulation of TWIST by HIF-1alpha promotes metastasis
    Muh Hwa Yang
    Institutes of Biochemistry and Molecular Biology, National Yang Ming University, No 155, Sec 2, Li Niong Street, Peitou, Taipei 112, Taiwan
    Nat Cell Biol 10:295-305. 2008
    ..These results provide evidence of a key signalling pathway involving HIF-1alpha and TWIST that promotes metastasis in response to intratumoural hypoxia...
  90. ncbi Src kinases as therapeutic targets for cancer
    Lori C Kim
    University of South Florida College of Medicine, Tampa, FL, USA
    Nat Rev Clin Oncol 6:587-95. 2009
    ..In preclinical studies these agents can suppress tumor growth and metastases. The agents seem to be safe in humans and could add to the therapeutic arsenal against subsets of cancers...
  91. ncbi RHO-GTPases and cancer
    Erik Sahai
    Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
    Nat Rev Cancer 2:133-42. 2002
    ..A branch of the RAS family--the RHO proteins--is also involved in cancer, but what is the role of these proteins and would they make good therapeutic targets?..
  92. ncbi Mechanisms of bone metastasis
    G David Roodman
    Department of Medicine, Division of Hematology Oncology, University of Pittsburgh, School of Medicine Hematology, The University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
    N Engl J Med 350:1655-64. 2004
  93. ncbi Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system
    Sabine Riethdorf
    Institute of Tumor Biology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Clin Cancer Res 13:920-8. 2007
    ..Here, we validated the analytic performance of this system for clinical use in patients with metastatic breast cancer...
  94. ncbi Lysyl oxidase is essential for hypoxia-induced metastasis
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 440:1222-6. 2006
    ..Furthermore, LOX may be required to create a niche permissive for metastatic growth. Our findings indicate that LOX is essential for hypoxia-induced metastasis and is a good therapeutic target for preventing and treating metastases...
  95. pmc Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process
    Uma R Chandran
    Departmental of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15260, USA
    BMC Cancer 7:64. 2007
    ..Understanding the differences in the biology of metastatic and organ confined primary tumors is essential for developing new prognostic markers and therapeutic targets...
  96. ncbi Hedgehog signalling in prostate regeneration, neoplasia and metastasis
    Sunil S Karhadkar
    Department of Molecular Biology and Genetics and the Howard Hughes Medical Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Nature 431:707-12. 2004
    ..Monitoring and manipulating Hh pathway activity may thus offer significant improvements in diagnosis and treatment of prostate cancers with metastatic potential...
  97. pmc Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, CRC 3 3940, 10 Center Dr MSC 1201, Bethesda MD 20892 1202, USA
    J Clin Oncol 23:2346-57. 2005
    ..We investigated the combination of lymphodepleting chemotherapy followed by the adoptive transfer of autologous tumor reactive lymphocytes for the treatment of patients with refractory metastatic melanoma...
  98. pmc Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts
    Yudi Pawitan
    Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
    Breast Cancer Res 7:R953-64. 2005
    ..Breast cancer expression profiling has so far mainly been used to identify women with a poor prognosis as candidates for adjuvant therapy but without demonstrated value for therapy prediction...
  99. ncbi Effector memory T cells, early metastasis, and survival in colorectal cancer
    Franck Pages
    INSERM UNITE 255, René Descartes Faculté de Médecine, Assistance Publique Hopitaux de Paris, Cordeliers Biomedical Research Center, University Paris 6, Paris, France
    N Engl J Med 353:2654-66. 2005
    ..The role of tumor-infiltrating immune cells in the early metastatic invasion of colorectal cancer is unknown...
  100. pmc Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility
    Silvia Giampieri
    Tumour Cell Biology Laboratory, CR UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Nat Cell Biol 11:1287-96. 2009
    ..Constitutive TGFbeta signalling promoted single cell motility and intravasation but reduced subsequent growth in the lungs. Thus, transient TGFbeta signalling is essential for blood-borne metastasis...
  101. pmc The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling
    Douglas S Micalizzi
    Program in Molecular Biology, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
    J Clin Invest 119:2678-90. 2009
    ..Our findings indicate that Six1, acting through TGF-beta signaling and EMT, is a powerful and global promoter of cancer metastasis...

Research Grants107 found, 100 shown here

  1. Inhibitors of 5alpha-reductase for acne therapy
    Lingna Li; Fiscal Year: 2002
    ..PROPOSED COMMERCIAL APPLICATIONS: Liposomal 4-MA will be developed as a topical selectively targeted therapeutic for acne for which they should be a very market. ..
  2. RHOMOCYCSTEINASE FOR HOMOCYSTEINE ASSAY
    Yuying Tan; Fiscal Year: 2002
    ..The tHCY enzymatic kits for these applications will be ready for commercial launch at this point. PROPOSED COMMERCIAL APPLICATION: Not Available ..
  3. Therapeutic hair follicle-derived neurospheres
    Meng Yang; Fiscal Year: 2007
    ..Human hair- follicle bulge cells will be further characterized and developed for therapeutic potential for nerve regeneration in Phase III. [unreadable]..
  4. Discovery of novel fluorescent reporter genes
    Ming Zhao; Fiscal Year: 2004
    ..Reporters with spectral properties that can be used for whole-body imaging of tumors in the lung and their metastases will be candidates for further development for numerous applications of multi-color imaging. ..
  5. MOLECULAR ANALYSIS OF THE ALPHA6-BETA4 INTEGRIN
    Filippo Giancotti; Fiscal Year: 2002
    ..We hope that these studies will help to clarify the function of alpha6beta4 in normal and neoplastic cells. ..
  6. Integrin alpha6beta4 Signaling in Prostate Carcinoma Growth and Invasion
    Filippo G Giancotti; Fiscal Year: 2010
    ..We will study the expression of alpha6beta4 during human prostate cancer progression and test the effect of beta4 signaling-inhibitory antibodies in xenograft models. ..
  7. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  8. Molecular Basis Of Renal Cell Carcinoma Response to SU11428
    Robert J Motzer; Fiscal Year: 2011
    ..These tumor and cell line-based studies lay a foundation for further molecular studies aimed at understanding the sensitivity/resistance of RCC to SU11248. ..
  9. Role of the Adaptor Protein Shc in Integrin Signaling
    Filippo Giancotti; Fiscal Year: 2007
    ..DNA microarray analysis of polysome-bound mRNAs will be employed to study the role that matrix control of mRNA translation plays in coordinating cell growth and cell division. ..
  10. Hypoxia-Inducible Factor 1 and Oxygen Homeostasis
    Gregg Semenza; Fiscal Year: 2009
    ....
  11. EXPRESSION OF HUMAN ERYTHROPOIETIN GENE
    Gregg Semenza; Fiscal Year: 2002
    ..abstract_text> ..
  12. Molecular Changes Associated with PCa bone metastases
    Kenneth Pienta; Fiscal Year: 2006
    ..This knowledge could lead to the development of better biomarkers of disease progression as well as targets for therapy. ..
  13. INTEGRATION OF FIBROBLAST FUNCTIONING IN WOUND HEALING
    Alan Wells; Fiscal Year: 2003
    ..Understanding the delicate balance of these molecular mechanisms is important for rationally designing interventions to achieve normal wound healing. ..
  14. Dermal-Epidermal Communication during Wound Healing
    Alan Wells; Fiscal Year: 2008
    ..These investigations will define key extracellular and intracellular molecules for wound resolution. These are potential targets for rationally designed interventions to promote normal wound healing and limit scarring. ..
  15. AFP-Based Immunotherapy for Hepatocellular Carcinoma
    Antoni Ribas; Fiscal Year: 2006
    ..In summary, I propose a clinically-oriented research program that translates this original work into novel, evidence-based immnunotherapy trials for hepatocellular carcinoma. ..
  16. Creation and demonstration of a palliative care research cooperative group
    Jean S Kutner; Fiscal Year: 2010
    ....
  17. Exercise in Patients with Advanced NSCLC: A Pilot Study
    Jennifer Temel; Fiscal Year: 2005
    ..abstract_text> ..
  18. 131 I-MIBG Escalating Dose Rapid Sequence Double Infusi*
    Katherine Matthay; Fiscal Year: 2004
    ..Significance: The higher tumor-specific radiation doses possible with this protocol may provide a treatment to improve response and survival in children with resistant neuroblastoma. ..
  19. Palliative Oxygen for the Relief of Breathlessness
    Amy Abernethy; Fiscal Year: 2007
    ..The results will also advance a long-standing international debate about the role of palliative oxygen for intractable dyspnea and it's funding. [unreadable] [unreadable] [unreadable]..
  20. Disparate Metastatic Breast Cancer Symptom Severity and Management Barriers
    Margaret Rosenzweig; Fiscal Year: 2007
    ..Supportive activities will take place at the Yale University School of Nursing, Harvard University and through the University of Wisconsin, Milwaukee. ..
  21. CHILDRENS CANCER GROUP
    Katherine Matthay; Fiscal Year: 2002
    ..Our strong biology research laboratories in brain tumors, neuroblastoma and myeloproliferative disorders are conducting multiple biology studies in the Group and providing new information for future studies. ..
  22. MENTORING FOR NEW CANCER THERAPEAUTICS
    Gary Schwartz; Fiscal Year: 2005
    ..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
  23. Causal Models for CVD Use by Aspirin and Vitamin E in the Women's Health Study
    Nancy Cook; Fiscal Year: 2008
    ..The findings of reduced risk of CVD mortality, however, as well as effects by age, should be explored further to clarify the public health message. [unreadable] [unreadable] [unreadable]..
  24. DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS
    HEINZ LENZ; Fiscal Year: 2002
    ....
  25. Orthotopic models of tumor angiogenesis and blood flow
    Meng Yang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  26. NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS
    Herbert Hurwitz; Fiscal Year: 2005
    ..4) To evaluate several potential refinements of this normal wound angiogenesis assay in healthy volunteers, and incorporate these refinements in to patient studies involving novel anti-angiogenesis agents. ..
  27. CANCER AND LEUKEMIA GROUP B
    MARY TAPLIN; Fiscal Year: 2002
    ..Major efforts have led to improvement in accrual to Group Studies and improvement in the quality of data submitted on CALGB clinical trials. ..
  28. Changes in Functional Status Across Therapy for Primary Glioma
    Lee Jones; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  29. Gene Repression by HSF1 during hyperthermia and stresses
    Stuart Calderwood; Fiscal Year: 2006
    ..Dominant negative inhibitors of HSF1 repression have been identified in this study and they will be used in transfected cells to study the cellular consequences of gene repression by HSF 1. ..
  30. Enzyme therapy for hyperhomocysteinemia
    Yuying Tan; Fiscal Year: 2005
    ..Phase II results will lead to an IND for MEGC-PEG-rMETase for end stage renal disease patients and other patients with intractable hyperhomocysteinemia and high cardiovascular disease mortality. ..
  31. FGF-Silyl-Heparin Cerebral Aneurysm Coils
    PAUL ZAMORA; Fiscal Year: 2002
    ..The Phase I studies will develop the coated coils and perform initial animal evaluations. ..
  32. MTOR as a Therapeutic Target in Childhood Cancer
    Peter Houghton; Fiscal Year: 2005
    ..abstract_text> ..
  33. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary K Schwartz; Fiscal Year: 2010
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
  34. Phase I Trial of Safingol and Cisplatin
    Gary Schwartz; Fiscal Year: 2006
    ..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
  35. ANGIOTENSIN II AND REGULATION OF MCP-1 GENE EXPRESSION
    Changyi Chen; Fiscal Year: 2002
    ....
  36. CARTILAGE CELL AND MATRIX RESPONSE TO JOINT LOADING
    Peter Torzilli; Fiscal Year: 2008
    ..If, as we believe, two distinct initiation mechanisms exist, then this would significantly alter how we study each disease process and how we will need to treat them to prevent the progression of the disease. [unreadable] [unreadable]..
  37. HIV/SIV ENVELOPE GLYCOPROTEIN EFFECTS ON ENDOTHELIA
    Changyi Chen; Fiscal Year: 2002
    ....
  38. Does NO mediate clinical anti-VEGF vascular effects
    Herbert Hurwitz; Fiscal Year: 2004
    ..However, to allow for potential clinical benefit, patients will be permitted to receive ongoing anti-VEGF therapy as deemed appropriate by their physician. ..
  39. SPECIAL POPULATIONS NETWORK FOR CANCER CONTROL
    Edith Mitchell; Fiscal Year: 2003
    ..abstract_text> ..
  40. GLYCOSPHINGOLIPIDS IN MURINE NEURODEGENERATIVE DISEASES
    THOMAS SEYFRIED; Fiscal Year: 2004
    ..Since there are no effective treatments for human ganglioside storages disease, the proposed research could offer a novel therapy for the early intervention of these neurodegenerative disorders. ..
  41. Matricellular proteins as regulators of tumor progression
    Rolf A Brekken; Fiscal Year: 2010
    ....
  42. A pharmacogenetic and pharmacodynamic study of erlotinib
    CHARLES RUDIN; Fiscal Year: 2004
    ..Defining the basis of this toxicity could also promote the development of EGFR-directed agents that may avoid such toxicity or that may be effective in a broader spectrum of cancer patients. ..
  43. Cartilage Degeneration Following Joint Trauma
    Peter Torzilli; Fiscal Year: 2003
    ....
  44. ROLE OF HSF2 IN THE STRESS RESPONSE TO HYPERTHERMIA
    Stuart Calderwood; Fiscal Year: 2002
    ..abstract_text> ..
  45. Chemoprevention of Head and Neck Cancer with ZD1839 and Celecoxib
    Dong Shin; Fiscal Year: 2008
    ..Biomarker changes will be correlated with cancer incidence by statistical analyses. We will also determine whether such biomarker changes can serve as intermediate endpoint(s) in this chemopreventive trial. ..
  46. Adenoviral GFP targeting of metastatic human tumors using multiple delivery route
    Hiroyuki Kishimoto; Fiscal Year: 2008
    ..Having obtained these results, we can move forward in the Phase II grant application with experiments to bring OBP-401 to the clinic for use in cancer surgery in human patients. [unreadable] [unreadable] [unreadable]..
  47. TARGETS OF AMINO ACID RESTRICTION IN PROSTATE CANCER
    Gary G Meadows; Fiscal Year: 2009
    ..This research could serve as the basis for future development of more specific antimetastatic, anti-invasive, apoptosis-based therapies for human prostate cancer. ..
  48. Dual-color tumor-host imaging models
    Meng Yang; Fiscal Year: 2007
    ..These models have significant commercial potential for discovery and development of stroma-targeted and anti-angiogenesis drugs. [unreadable] [unreadable] [unreadable]..
  49. Inland Northwest Cancer Conference
    GARY MEADOWS; Fiscal Year: 2004
    ..The 2004 conference entitled "Bridging the Gap, Breakthroughs in Cancer Care and Research" will be held on November 12th and 13th at the Davenport Hotel in Spokane, WA. ..
  50. Targeted tumoricidal bacteria
    Ming Zhao; Fiscal Year: 2007
    ..Future human trials of the tumor-killing bacteria can be held after the Phase I and Phase II grant periods are completed. [unreadable] [unreadable] [unreadable]..
  51. Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
    Herbert I Hurwitz; Fiscal Year: 2010
    ..This work has the potential to improve both the safety and efficacy of this novel class of drugs. I;' ..
  52. Effects of HAART drugs on endothelial dysfunction of pu*
    Changyi Chen; Fiscal Year: 2009
    ..abstract_text> ..
  53. FDG PET-CT in Metastatic Prostate Cancer
    Hossein Jadvar; Fiscal Year: 2010
    ..Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ..
  54. GLYCOSPHINGOLIPIDS IN MURINE NEURODEGENERATIVE DISEASES
    THOMAS SEYFRIED; Fiscal Year: 2009
    ..The proposed studies will provide essential information on combinatorial therapies for the ganglioside storage diseases and will have translational benefit to the clinic. ..
  55. Targeted Molecular Therapeutics for Melanoma: CCI-779 and Bevacizumab
    Craig Slingluff; Fiscal Year: 2008
    ..The following proposal is a clinical trial to evaluate the effects of bevacizumab and CCI-779, which interfere with vascularization and tumor growth, for the treatment of melanoma. [unreadable] [unreadable] [unreadable]..
  56. Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small
    CHARLES RUDIN; Fiscal Year: 2008
    ..If successful, this approach could alter the poor prognosis of individuals with this disease. [unreadable] [unreadable] [unreadable]..
  57. Multi-peptide Vaccine Administered with Cyclophosphamide for High-risk Melanoma
    CRAIG LEE SLINGLUFF; Fiscal Year: 2010
    ....
  58. Imageable tumor-targeting bacteria
    Ming Zhao; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  59. Glycosphingolipid Effects on Brain Tumor Angiogenesis
    THOMAS SEYFRIED; Fiscal Year: 2006
    ..The proposed research will better define the relationship between gangliosides and tumor angiogenesis and can lead to new experimental strategies for managing brain tumors. ..
  60. Thrombospondins and Atherothrombosis
    Edward Plow; Fiscal Year: 2004
    ..Together, these studies should provide a rigorous test of the hypothesis and extend our knowledge of the roles of the TSPs in cardiovascular biology. ..
  61. Survey of oncology providers on psychosocial distress
    William Pirl; Fiscal Year: 2005
    ..abstract_text> ..
  62. MECHANISM OF THYMIC ATROPHY INDUCED BY ALCOHOL
    GARY MEADOWS; Fiscal Year: 2006
    ..The long term objective of this research is to understand the mechanism underlying the loss in thymic cellularity induced by high alcohol consumption and to determine the reversibility of this effect. ..
  63. VACCINES WITH MHC CLASS II-RESTRICTED MELANOMA PEPTIDES
    Craig Slingluff; Fiscal Year: 2004
    ....
  64. DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY
    HEINZ LENZ; Fiscal Year: 2004
    ..This proposal will feature three beginning clinicians responsible for three different patient oriented projects taking advantage of our successful program in molecular outcome research. ..
  65. Thromboresistant vascular grafts:heparin-peptidomimetics
    PAUL ZAMORA; Fiscal Year: 2004
    ..abstract_text> ..
  66. Molecular Surgeon Symposium on Vascular Injury, Repair
    Changyi Chen; Fiscal Year: 2005
    ..A pre-approved letter for acceptance of submission of this application from NIH/NHLBI is included. ..
  67. MULTI-EPITOPE MELANOMA PEPTIDE VACCINATION WITH GM-CSF
    Craig Slingluff; Fiscal Year: 2004
    ..abstract_text> ..
  68. Depsipeptide for the Treatment of Head and Neck Cancer
    Missak Haigentz; Fiscal Year: 2006
    ..abstract_text> ..
  69. HIV PROTEASE INHIBITORS EFFECT--NENDOTHELIAL DYSFUNCTION
    Changyi Chen; Fiscal Year: 2004
    ..Together, the integrated basic science, non-human primate and human investigations offer a multi disciplinary approach to the understanding and prevention of protease inhibitor-associated vascular complications. ..
  70. Regulation of Angiogenesis by C CAM1
    Sue Hwa Lin; Fiscal Year: 2004
    ..Achieving these aims will provide valuable information for applying CCAM1 for prostate cancer therapy and for developing C-CAM1 combination therapy. ..
  71. THE STRUCTURE AND FUNCTION OF PLATELET GPIIB-IIIA
    Edward Plow; Fiscal Year: 2003
    ..At the same time, these studies may have direct bearing on the use and future development of the GPIIb-IIIa blockers as antithrombotic agents. ..
  72. MOLECULAR REGULATION OF THE HUMAN BRCA 1 GENE
    DONATO ROMAGNOLO; Fiscal Year: 2003
    ..Specific aim #3 will examine the function of BRCA-1 in cell cycle regulation at different levels of genotoxic damage induced by PAHs. ..
  73. RANDOMIZED ADJUVANT THERAPY OF HEAD AND NECK CANCER
    Dong Shin; Fiscal Year: 2001
    ....
  74. 2004 Hemostasis Gordon Research Conference
    Edward Plow; Fiscal Year: 2004
    ..The Hemostasis Gordon Conference has been a highly successful and enjoyable meeting, frequently identified as the best meeting attended by participants; and we believe that the current program has the potential to extend this tradition. ..
  75. CYP1A1 and CYP1B1 genes in race-related Prostate Cancer
    Rajvir Dahiya; Fiscal Year: 2007
    ..We will also investigate whether estrogen hydroxylase activities and estrogen metabolites (2-OHE2 and 4-OH-E2) are associated with prostate cancer recurrence. ..
  76. VH IG PEPTIDE VACCINES FOR HUMAN B CELL MALIGNANCIES
    Richard Bankert; Fiscal Year: 2003
    ..Valuable insights are also anticipated with respect to designing vaccination protocols for other tumors where a tumor specific antigen has been identified. ..
  77. Ganglioside Regulation of NFkbeta and Apoptosis
    James Finke; Fiscal Year: 2005
    ..These studies will provide insight into how gangliosides inhibit NFKB and survival gene expression, leading to increased T cell sensitivity to apoptosis. ..
  78. Therapy of Melanoma with Bortezomib and Interferon-alpha
    William Carson; Fiscal Year: 2007
    ..These studies will help to define the specific apoptotic and immunostimulatory pathways that are being modulated by the combination of bortezomib and IFN-a2b. [unreadable] [unreadable]..
  79. Soy Food and Coronary Heart Disease in Women
    Xiao Ou Shu; Fiscal Year: 2008
    ....
  80. HPV DNA VACCINE FOR CERVICAL PRE NEOPLASIA
    Jeffrey Weber; Fiscal Year: 2003
    ..To insure that spontaneous regression does not account for a portion of the responses, baseline measurements will be followed one month later by a second set of assessments prior to the start of the vaccine. ..
  81. 2nd International Conference on Prostate Cancer Research
    David Lubaroff; Fiscal Year: 2002
    ..Selection of the travel awardees will be made by a subcommittee of the Organizing Committee and will be based upon the quality of the research contained in the submitted abstracts. ..
  82. Clinical Trials Methods Workshop - Europe
    Daniel Von Hoff; Fiscal Year: 2008
    ..And, finally, a proven evaluation system is in place to demonstrate that the Workshop will meet its objectives. ..
  83. LETHAL MUTAGENESIS OF HIV BY DEOXYNUCLEOSIDE ANALOGS
    LAWRENCE LOEB; Fiscal Year: 2002
    ....
  84. Flourescent Lifetime Imaging Microscopy (FLIM)
    John Condeelis; Fiscal Year: 2005
    ..As discussed in the budget justification, the system we request will solve the problems of speed, sensitivity, and quantitation for an expert user group. ..
  85. Plasmalogen Metabolism by iPLA2 in Ischemic Myocardium
    Jane McHowat; Fiscal Year: 2005
    ..Our long-term objectives are to determine the metabolic pathways that are appropriate targets for novel therapeutic strategies to alleviate the morbidity and mortality of ischemic heart disease in man. ..
  86. Modulation of Tumor CEA Levels for an Anti-CEA Vaccine
    William Carson; Fiscal Year: 2006
    ..These analyses will allow us to determine whether the expression of the CEA tumor antigen can be modulated by cytokine treatment and if this translates into an improved anti-tumor response. ..
  87. IL-12 as an Adjuvant for a Melanoma Peptide Vaccine
    Jeffrey Weber; Fiscal Year: 2003
    ..The results of those assays will be used to design randomized phase III trials for resected high risk melanoma and to develop strategies for overcoming antigen-specific unresponsiveness in melanoma patients. ..
  88. HB-EGF AND ITS RECEPTORS
    Michael Klagsbrun; Fiscal Year: 2003
    ..abstract_text> ..
  89. Fractures, Heart Disease, and Stroke on Aromatase Inhibitors
    Nancy L Keating; Fiscal Year: 2010
    ....
  90. AIDS MALIGNANCY CONSORTIUM
    Joseph Sparano; Fiscal Year: 2005
    ..abstract_text> ..
  91. Implications of Retinoid-Induced CD38 Antigen Expression
    Kapil Mehta; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  92. Local Therapy of Breast Cancer in Community Populations
    Nancy Keating; Fiscal Year: 2007
    ..Moreover, the work will provide insight into different techniques for the analysis of observational data. ..
  93. CELLULAR AND MOLECULAR BASIS OF HIV BASED THROMBOCYTOPEN
    Mariusz Ratajczak; Fiscal Year: 2002
    ..In toto, the studies proposed in this grant will increase the knowledge about pathogenesis of AIDS associated thrombocytopenia and may lead to development of new strategies for its treatment of prevention. (End of Abstract) ..
  94. CIRCULATING INHIBITORS OF ENDOTHELIAL CELL GROWTH
    Michael Klagsbrun; Fiscal Year: 2008
    ..Currently, all angiogenesis inhibitors in clinical application are employed only after the angiogenic switch. [unreadable] [unreadable]..
  95. Dendritic Cell Vaccination During Lymphoid Reconstitution
    Jeffrey Weber; Fiscal Year: 2008
    ..Toxicity as well as clinical response will be secondary endpoints. The cohort with the optimal level of immune response will be taken forward in future studies. ..
  96. CTLA-4 Inhibition and Autoimmunity in Melanoma
    Jeffrey Weber; Fiscal Year: 2008
    ..abstract_text> ..
  97. Nitric oxide as a target for dietary intervention in colitis
    Michael Wargovich; Fiscal Year: 2007
    ..The overall goal of this application is to provide the public some assurance that the dietary supplements gingko and ginseng, have the capacity to alleviate colitis. [unreadable] [unreadable] [unreadable]..
  98. THE ROLE OF RB IN THE RETINA & OTHER TISSUES
    JAMES HARBOUR; Fiscal Year: 2009
    ..Consequently, these aims are highly relevant to the vision statement of the NEI, and they address several major program goals and objectives of the Retinal Diseases Program. ..
  99. The CXCR4-SDF-1 Axis in Metastatic Rhabdomyosarcoma
    Mariusz Ratajczak; Fiscal Year: 2009
    ..This work will be of relevance for designing strategies to block the SDF-1-CXCR4 axis to treat CXCR4-positive cancers. ..